European Commission Expands Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Regardless of PD-L1 Status

European Commission Broadens Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Regardless of PD-L1 Status Gilead Sciences, Inc.announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab…

Read MoreEuropean Commission Expands Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Regardless of PD-L1 Status

ORZEYFUL (oveporexton) Receives Japanese Approval as the First and Only Treatment Targeting the Underlying Cause of Narcolepsy Type 1

ORZEYFUL (oveporexton) Gains Japanese Approval as the First and Only Medicine Addressing the Underlying Cause of Narcolepsy Type 1 Takeda has announced that Japan’s Ministry of Health, Labour and Welfare…

Read MoreORZEYFUL (oveporexton) Receives Japanese Approval as the First and Only Treatment Targeting the Underlying Cause of Narcolepsy Type 1